- Research article
- Open Access
- Open Peer Review
Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway
- Hongbo Li†1, 2,
- Zhenkai Wang†2,
- Jie Zhang3,
- Youlei Wang3,
- Chen Yu3,
- Jinjin Zhang3,
- Xiaodong Song3Email author and
- Changjun Lv1, 2, 3Email author
© The Author(s). 2018
- Received: 17 April 2018
- Accepted: 26 July 2018
- Published: 9 August 2018
Feifukang (FFK) is a traditional Chinese medicine composed of herbs that protect lung function. However, difficulty arises regarding the clinical application of FFK due to the complex mechanism of Chinese medicines. This study aimed to investigate the efficacy of FFK and explore its targeted genes and pathways.
Histopathological changes and collagen deposition were measured to evaluate the effect of FFK on bleomycin-induced pulmonary fibrosis in mice. The differentially expressed targeted genes and pathways were first screened using RNA sequencing. Then network pharmacology and other experiments were conducted to confirm RNA sequencing data.
FFK treatment reduced the pathological score and collagen deposition, with a decrease in α-SMA and collagen. RNA sequencing and network pharmacology results all showed that FFK can ameliorate pulmonary fibrosis through multi-genes and multi-pathways. The targeted genes in JAK-STAT signaling pathway are some of the most notable components of these multi-genes and multi-pathways. Further experiments illustrated that FFK regulated phosphorylation of SMAD3, STAT3 and JAK1, and their co-expressed lncRNAs, which all are the important genes in JAK-STAT signaling pathway.
FFK can ameliorate pulmonary fibrosis by inhibiting JAK-STAT signaling pathway and has potential therapeutic value for lung fibrosis treatment. Our study provides a new idea for the study of traditional Chinese medicine.
- Pulmonary fibrosis
- Traditional Chinese medicine
Pulmonary fibrosis occurs in various clinical settings and can be life threatening ; this disease is characterized by altered cellular composition and homoeostasis in peripheral lungs, thereby leading to excessive accumulation of extracellular matrix and loss of lung function . In the past decade, researchers described several cellular and molecular signaling pathways implicated in the pathogenesis of pulmonary fibrosis; these results led to identification of new therapeutic targets. Many therapies are used in pulmonary fibrosis treatment; however, only a few can increase the survival rates and improve the quality of life of patients. Pirfenidone and nintedanib were approved for the treatment of pulmonary fibrosis [3, 4], but their side-effects, such as photosensitivity, gastrointestinal symptoms, and liver function test abnormalities, were often observed [5, 6]. This situation occurs because pulmonary fibrosis has complex regulatory networks that repress or induce the expression of a set of related target genes and pathways. Emerging evidence showed that genetic, epigenetic, and proteomic factors are involved in regulatory networks during development of pulmonary fibrosis. Instead of working through one pathway, these networks regulate the expression of entire sets of fibrosis-relevant genes by turning the pathways on or off [7, 8].
Chinese herbs exhibit low toxicity and no side effects for disease treatment. Therefore, traditional Chinese medicine (TCM) features the long history of disease treatment [9, 10]. However, the unclear mechanism of TCM has sparked criticism when this medicine has become more popular today [11, 12]. Thus, investigating the targeted genes and pathways is important to the modernization of TCM. Multiple approaches, including network pharmacology and pharmaco-genomics, have been utilized to investigate the mechanism of TCM. Qing-Luo-Yin and other TCMs have been studied by using these approaches [13–15]. As another novel high-throughput technique, RNA sequencing has become a potential research approach in disease treatment. However, this technology has not been popularized in TCM research.
Feifukang, also known as pulmonary rehabilitation mixture, comprises eight herbs including Astragalus membranaceus (Fisch) Bge., Codonopsis pilosula (Franch.) Nannf., Ophiopogon japonicus, Schisandra chinensis, Panax notoginseng (Burk.) F. H. Chen., Bulbus fritillariae thunbergii, Rhizoma anemarrhenae, and Glycyrrhiza uralensis, which is designed by our group based on clinical practice and drug screening for several decades. Through the experiment and the clinical test, FFK has been proven to have good curative effect for patients with pulmonary fibrosis. Our previous study demonstrated that FFK can prevent experimental pulmonary fibrosis in vitro and in vivo . However, a critical issue must be addressed, namely, its mechanism of multi-genes and multi-pathways in treating pulmonary fibrosis. In the present study, we first combined RNA sequencing and network pharmacology to analyze the targeted multi-genes and multi-pathways of FFK in pulmonary fibrosis treatment. We hope provide the theoretical and experimental basis for the clinical application of FFK for lung fibrosis treatment. Meanwhile, we also hope to provide a new idea for the study of TCM.
Animal model and ethics statement
Eight-week-old C57BL/6 mice were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China). All animal experiments were performed according to regulations established by the Ethics Committee on Animal Experiments of Binzhou Medical University (Approval number: No. 201704001). Mice were housed under a 12 h light/dark cycle and provided free access to food and water. Pulmonary fibrosis model was established as previously described . Briefly, mice were administered with 5 mg/kg saline-dissolved bleomycin (BLM) via single intratracheal instillation under anesthesia. Sham control mice received an equal volume of saline only. On day 2, mice were randomly divided into the following groups (10 mice each): sham, BLM, and BLM + FFK-treated groups. FFK (3.0 g/kg) was administered orally once daily. Lungs of all mice were removed on day 28 for further analysis.
According to the 2013 AVMA Guidelines for the Euthanasia of Animals, intraperitoneal injection of ethanol is acceptable with conditions for use in animals . Moreover, according to the method described by Allen-Worthington et al. , 70% (v/v) ethanol in 0.9% sterile saline was applied in the ventral chest region for getting deep anesthesia.
Hematoxylin and eosin (H&E) and Masson’s trichrome staining
Histopathological changes and collagen deposition were assessed by the H&E and Masson staining, respectively. Lung tissues were fixed with 4% formalin overnight, dehydrated in 70% ethanol and cleared in xylene. Transverse sections of 4 um thickness were stained with H&E or Masson’s trichrome staining as previously described .
Lung specimens were washed with saline and hydrolyzed with 0.6% hydrochloric acid at 100 °C for 5 h. Hydrolysates were neutralized with sodium hydroxide and diluted with distilled water. Hydroxyproline level in hydrolysates was colorimetrically determined by absorbance at 560 nm with p-dimethylaminobenzaldehyde and expressed as μg/mg wet tissue.
Twenty mircograms of protein sample was subjected to 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis, transferred onto polyvinylidene difluoride membranes, and blocked with 7% non-fat milk in Tris-buffered saline and Tween-20 (TBST; 50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 0.1% Tween-20). Membranes were washed thrice with TBST buffer and incubated at 4 °C overnight with specific antibodies. After washing with TBST, membranes were incubated with horseradish peroxidase-labeled IgG for 1.5 h. Membranes were then washed with TBST, incubated with ECL reagent, and exposed. Then, membranes were subsequently stripped and re-probed with glyceraldehyde 3-phosphate dehydrogenase antibody, which served as loading control.
A total amount of 2 μg RNA per sample was used as input material for the RNA sample preparations. Sequencing libraries were generated using NEBNext® Ultra™ RNA Library Prep Kit for Illumina® (#E7530L, NEB, USA) following the manufacturer’s recommendations and index codes were added to attribute sequences to each sample. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried out using divalent cations under elevated temperature in NEBNext First Strand Synthesis Reaction Buffer (5X). First strand cDNA was synthesized using random hexamer primer and RNase H. Second strand cDNA synthesis was subsequently performed using buffer, dNTPs, DNA polymerase I and RNase H. The library fragments were purified with QiaQuick PCR kits and elution with EB buffer, then terminal repair、A-tailing and adapter added were implemented. The aimed products were retrieved by agarose gel electrophoresis and PCR was performed, then the library was completed. RNA concentration of library was measured using Qubit® RNA Assay Kit in Qubit® 3.0 to preliminary quantify and then dilute to 1 ng/μL. Insert size was assessed using the Agilent Bioanalyzer 2100 system (Agilent Technologies, CA, USA), and qualified insert size was accurately quantified using StepOnePlus™ Real-Time PCR System (Library valid concentration>10 nM). The clustering of the index-coded samples was performed on a cBot cluster generation system using HiSeq PE Cluster Kit v4-cBot-HS (Illumina) according to the manufacturer’s instructions. After cluster generation, the libraries were sequenced on an Illumina Hiseq 4000 platform and 150 bp paired-end reads were generated.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). RNA quantity and quality were measured using the NanoDrop 2000 spectrophotometer (Thermo scientific, Waltham, USA) and RNA integrity was assessed by standard denaturing agarose gel electrophoresis. Complementary DNA synthesis was performed using the M-MLV reverse transcriptase kit (Invitrogen Carlsbad, CA, USA) following the manufacturer’s instructions. qRT-PCR was performed using a SYBR green-based PCR master mix kit (Takara, Shiga, Japan) on a Rotor Gene 3000 real-time PCR system from Corbett Research (Sydney, Australia).
Analysis of network pharmacology
FFK comprises Astragalus membranaceus (Fisch) Bge., Codonopsis pilosula (Franch.) Nannf., Ophiopogon japonicus, Schisandra chinensis, Panax notoginseng (Burk.) F. H. Chen., Bulbus fritillariae thunbergii, Rhizoma anemarrhenae, and Glycyrrhiza uralensis. Active chemical components of these plants were collected and extracted from Chinese Pharmacopoeia 2015 edition, Web of Science, http://www.wanfangdata.com.cn/, http://www.cnki.net/, and www.ncbi.nlm.nih.gov/pubmed/. After reviewing databases, we extracted contents of various medicinal ingredients, and relevant activity reports were considered. Collected compounds included the main components of FFK. We encoded chemical compounds in the Traditional Chinese Medicine Systems Pharmacology database (http://sm.nwsuaf.edu.cn/lsp/index.php) to screen primary bioactive components using the absorption distribution metabolism excretion (ADME) system. Oral bioavailability (OB) totaled >10%, and drug likeness reached >0.04; these variables were used as thresholds for further extraction and optimization of medicinal ingredients. Molecules satisfying the criteria were used as bioactive compounds for further analysis.
Cytoscape is one of the most comprehensive tools for thorough analysis of biological networks. Various plugins extend functionality of Cytoscape by providing visualization and analysis of protein–protein interaction, gene regulation, gene co-expression, metabolism, signaling, and ecological networks as previously described [20, 21]. We extracted compounds covering primary drug-likeness component of FFK and encoded them into Cytoscape 3.2.1 software to construct a compound-medicine network. Subsequently, target bank, drug bank, binding DB, and potential drug target database were used to validate associative targets. Potential effective chemical compounds were inputted into the software to establish a compound-target network. The software was also used to construct a target-pathway network and explain target participation in pathways. Multiple targets indicated integral roles of FFK in IPF by sharing synergy targets of different compounds.
Data were expressed as mean ± standard deviation (SD) of the indicated number of independent experiments. Statistical analyses was performed with SPSS 16.0 software using one-way analysis of variance and Student’s t-test. Statistically significant difference was considered at p < 0.05.
Amelioration of FFK on BLM-induced pulmonary fibrosis in mice
Regulation of FFK in pulmonary fibrosis-associated mRNAs
Network pharmacology offers a approach of exploring drug targeted genes and identifying potential active ingredients in TCM research. Hence, we confirm the RNA sequencing data by using network pharmacology to analyze the compound–medicine, compound–target, and target–pathway networks of FFK according to the ADME system.
Ninety bioactive compounds filtered through the ADME system in PRM
Timosaponin A III_qt
Calycosin affects proliferation, metastatic recurrence, and metastasis of A549 cells by regulating the protein expression levels of matrix metalloproteinases (MMPs) through the inhibition of the protein kinase C alpha/extracellular signal-regulated kinase 1/2 pathway . Calycosin-7-O-β-D-glucoside can promote oxidative stress-induced cytoskeleton reorganization through the integrin-linked kinase signaling pathway in vascular endothelial cells . Formononetin, specifically 7-hydroxy-3-(4-methoxyphenyl)-4 h-chromen-4-one, is the aglycone that was hydrolyzed in vivo from ononin. This aglycone can inhibit the inflammation of lipopolysaccharide-induced acute lung injury in mice; this type of injury is associated with the induced expression of peroxisome proliferator-activated receptor-γ and the suppressed proliferation of human non-small cell lung cancer through cell cycle arrest and apoptosis [25, 26]. Formononetin can also inhibit the migration and invasion of breast cancer cells by suppressing MMP2 and MMP9 through phosphoinositide 3-kinase/protein kinase B (PI3K–Akt) signaling pathways .
Among the 129 targets, 83 were associated with pathways related to progression of pulmonary fibrosis, and the remaining 46 were associated with the pathophysiology of the disease. For example, monoamine oxidase (MAO) B and MAO A are associated with histidine metabolism. Prostaglandin G/H synthase 1 (PTGS1), arachidonate 5-lipoxygenase, and several other targets are associated with arachidonic acid metabolism, which is probably associated with progression of inflammation related to pulmonary fibrosis. Among these targets, estrogen receptor possesses the highest number of connected ingredients, which are associated with endocrine and other factor-regulated calcium reabsorption processes. PTGS2 and thrombin play pivotal roles in inflammatory and tissue repair responses through fibrin generation and activation by coagulation pathways in acute and fibrotic lung injury . Several other targets are associated with other diseases. For example, retinoid X receptor beta and tumor protein p53 RELA are associated with tuberculosis and small-cell lung cancer.
Involvement of JAK-STAT in the antifibrotic pathway of FFK
Analysis of co-expressed long noncoding RNA (lncRNA) with JAK-STAT pathway
In this study, the effect of FFK on BLM-induced lung fibrogenesis and its anti-fibrotic signaling pathway were investigated in mice. Our results showed that FFK significantly decreased the alveolar wall thickness and collagen fiber formation. These anti-fibrotic effects of FFK may be mediated by blocking the JAK-STAT signaling pathway.
Pulmonary fibrosis is an interstitial lung disease associated with aging and characterized by histopathological patterns of common interstitial pneumonia . Epithelial cells, resident fibroblasts, and immune cells communicate with one another in a complex mechanism, which evolves to initiate and promote fibrosis . However, no current therapeutic approach can treat the disease. Alternative herbal medicines, which are characterized as multiple compounds and targets, exhibit advantages in the treatment of pulmonary fibrosis. Unfortunately, the detailed molecular signaling pathway remains intractable because the potential targets and active substances of herbs are difficult to identify and analyze [37, 38]. High-throughput technologies, such as RNA sequencing and network pharmacology, offer approaches for exploring drug targets and identifying potential active ingredients in TCM . In this study, the targeted genes and signaling pathways in FFK treatment were analyzed by using RNA sequencing and network pharmacology. The RNA sequencing findings showed that FFK can ameliorate pulmonary fibrosis through multi-genes and multi-pathways. Particular genes, including JAK-STAT family members (Jak, Stat), JAK-STAT signaling regulators (Socs, Bcl2l1), and STAT-interacting transcription factors and regulators (Smad, Nfkb1), are some of the most notable components of the JAK-STAT signaling pathway.
An integrated systematic network pharmacological method was further utilized to explore the complex therapeutic mechanism of FFK and confirm the RNA sequencing data. The results showed that FFK played an important role in oxidative phosphorylation, apoptosis, inflammation, and regulation of autophagy, cell adhesion molecules, and extracellular matrix–receptor interaction, which are regulated by JAK-STAT, PI3K–Akt, TGF-β, and other signaling pathways. As a TCM with combined anti-inflammatory, anti-oxidant, and anti-fibrotic effects, FFK exhibits therapeutic potential for pulmonary fibrosis.
The influence of FFK on JAK-STAT signaling pathway was further examined based on these results. ADAM17 is a molecular switch that controls immune responses, tissue regeneration, and cancer development . This gene is upregulated in tumor cells almost ubiquitously  and is rarely reported in fibrotic diseases. Our previous study showed that ADAM17 is a target gene of miR-708-3p, which can induce aberrant fibrosis via STAT3-dependence on ADAM17 signaling pathways . In the current study, the expression level of JAK1, STAT3 and ADAM17 decreased in FFK treatment group compared to BLM treatment group, thus indicating the possible pathways implicated in lung fibrosis as targets of therapeutic attempts. What is the rationale behind FFK mediated JAK-STAT signaling pathway? Considering the mechanism diversity and complexity for drug action, protein phosphorylation was chose to demonstrate how FFK regulated JAK-STAT signaling pathway. Protein phosphorylation, as an extremely important protein posttranslational modification, participates in almost all life activities and plays important roles in cell signal transduction. Our result showed that FFK decreased the levels of p-SMAD3, p-JAK1, p-STAT3. We inferred that FFK blocked JAK-STAT pathway through regulating the relevant protein phosphorylation. Certainly, cellular transmembrane signal transduction is in a complicated way, experiments will be designed to determine the FFK regulation on JAK-STAT pathway for future research.
High-throughput technologies revealed that only 2% of the transcribed genome codes are attributed to proteins. With the wide-scale adoption of high-throughput sequencing techniques, these noncoding RNAs were described as a novel drug targets or biomarkers of various diseases. These RNAs also represent a potential research hotspot in disease treatment. Among the various types of noncoding RNAs, lncRNA has attracted increasing attention . Here, we revealed that the lncRNAs target JAK-STAT signaling pathway regulate the anti-pulmonary fibrosis mechanism of FFK. Certainly, further experiments should be designed to determine the relationship between FFK and lncRNAs-mediated pulmonary fibrosis for future research.
This work studied the anti-pulmonary fibrosis and signaling pathways of FFK. Results can remarkably explain that FFK showed efficacy as pulmonary fibrosis treatment through multi-genes and multi-pathways. The targeted genes in JAK-STAT signaling pathway are some of the most notable components of these multi-genes and multi-pathways. We hope provide the theoretical and experimental basis for the clinical application of FFK for lung fibrosis treatment. We also hope to provide a new idea for the study of TCM.
We are grateful to the members of the medicine laboratory for their excellent work.
This work was supported by National Natural Science Foundation of China (31470415, 31670365, 81670064, 81741170, 81273957), Important Project of Science and Technology of Shandong Province (2014GSF119014), Natural Science Foundation of Shandong Province (ZR2016HP34).
Availability of data and materials
The datasets used and analysed during the current study available from the corresponding author on reasonable request.
This study was designed by CJL, XDS and JJZ, HBL, ZKW, JZ, CY and YLW performed all the experiments, and XDS drafted the manuscript. All of the authors have read and approved the final manuscript. All authors agree with publication of this paper.
Ethics approval and consent to participate
We had complied with the ethics standard for research activity established at Binzhou Medical University. This research work was approved by Ethical Review Committee of Binzhou Medical University, China (Approval number: No. 201704001).
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Jiang D, Liang J, Hodge J, Lu B, Zhu Z, Yu S, et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. J Clin Invest. 2004;114(2):291–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.View ArticlePubMedGoogle Scholar
- King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.View ArticlePubMedGoogle Scholar
- Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82.View ArticlePubMedGoogle Scholar
- Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–53.View ArticlePubMedPubMed CentralGoogle Scholar
- Richeldi L, Cottin V, du Bois RM, Selman M, Kimura T, Bailes Z, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS® trials. Respir Med. 2016;113:74–9.View ArticlePubMedGoogle Scholar
- Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012;380(9842):680–8.View ArticlePubMedGoogle Scholar
- King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949–61.View ArticlePubMedGoogle Scholar
- Lv C, Wu X, Wang X, Su J, Zeng H, Zhao J, et al. The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: a general template for research on TCMs. Sci Rep. 2017;7(1):352.View ArticlePubMedPubMed CentralGoogle Scholar
- Li X, Xin P, Wang C, Wang Z, Wang Q, Kuang H. Mechanisms of traditional Chinese medicine in the treatment of mammary gland hyperplasia. Am J Chin Med. 2017;45(3):443–58.View ArticlePubMedGoogle Scholar
- Coghlan ML, Haile J, Houston J, Murray DC, White NE, Moolhuijzen P, et al. Deep sequencing of plant and animal DNA contained within traditional Chinese medicines reveals legality issues and health safety concerns. PLoS Genet. 2012;8(4):e1002657.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A. 2012;109(21):8241–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang B, Wang X, Li S. An integrative platform of TCM network pharmacology and its application on a herbal formula, Qing-Luo-Yin. Evid Based Complement Alternat Med. 2013;2013:456747.PubMedPubMed CentralGoogle Scholar
- Tang HC, Huang HJ, Lee CC, Chen CYC. Network pharmacology-based approach of novel traditional Chinese medicine formula for treatment of acute skin inflammation in silico. Comput Biol Chem. 2017;71:70–81.View ArticlePubMedGoogle Scholar
- Suo T, Liu J, Chen X, Yu H, Wang T, Li C, et al. Combining chemical profiling and network analysis to investigate the pharmacology of complex prescriptions in traditional Chinese medicine. Sci Rep. 2017;7:40529.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang L, Ji YX, Jiang WL, Lv CJ. Protective roles of pulmonary rehabilitation mixture in experimental pulmonary fibrosis in vitro and in vivo. Braz J Med Biol Res. 2015;48:545–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Zhang JJ, Xu P, Wang YL, Wang MR, Li HB, Lin SC, et al. Astaxanthin prevents pulmonary fibrosis by promoting myofibroblast apoptosis dependent onDrp1-mediated mitochondrial fission. J Cell Mol Med. 2015;19(9):2215–31.View ArticlePubMedPubMed CentralGoogle Scholar
- Leary SL, Underwood W, Anthony R, Gwaltney-Brant S, Poison A, Meyer R. AVMA guidelines for the euthanasia of animals: 2013 edition. Schaumburg: American Veterinary Medical Association; 2013.Google Scholar
- Allen-Worthington KH, Brice AK, Marx JO, Hankenson FC. Intraperitoneal injection of ethanol for the euthanasia of laboratory mice (Mus musculus) and rats (Rattus norvegicus). J Am Assoc Lab Anim Sci. 2015;54(6):769–78.PubMedPubMed CentralGoogle Scholar
- Duren W, Weymouth T, Hull T, Omenn GS, Athey B, Burant C, et al. MetDisease–connecting metabolites to diseases via literature. Bioinformatics. 2014;30(15):2239–41.View ArticlePubMedPubMed CentralGoogle Scholar
- Mustafin ZS, Lashin SA, Matushkin YG, Gunbin KV, Afonnikov DA. Orthoscape: a cytoscape application for grouping and visualization KEGG based gene networks by taxonomy and homology principles. BMC Bioinformatics. 2017;18(Suppl 1):1427.PubMedGoogle Scholar
- Zhao J, Ren Y, Qu Y, Jiang W, Lv C. Pharmacodynamic and pharmacokinetic assessment of pulmonary rehabilitation mixture for the treatment of pulmonary fibrosis. Sci Rep. 2017;7(1):3458.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheng XD, Gu JF, Yuan JR, Feng L, Jia XB. Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC- α/ERK1/2 pathway: an in vitro investigation. Mol Med Rep. 2015;13(4):3709–10.View ArticleGoogle Scholar
- Jiang YH, Sun W, Li W, Hu HZ, Zhou L, Jiang HH, et al. Calycosin-7-O-β-D-glucoside promotes oxidative stress-induced cytoskeleton reorganization through integrin-linked kinase signaling pathway in vascular endothelial cells. BMC Complement Altern Med. 2015;15:315.View ArticlePubMedPubMed CentralGoogle Scholar
- Ma Z, Ji W, Fu Q, Ma S. Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression. Inflammation. 2013;36(6):1560–6.View ArticlePubMedGoogle Scholar
- Yang Y, Zhao Y, Ai X, Cheng B, Lu S. Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. Int J Clin Exp Pathol. 2014;7(12):8453–61.PubMedPubMed CentralGoogle Scholar
- Zhou R, Xu L, Ye M, Liao M, Du H, Chen H. Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res. 2014;46(11):753–60.View ArticlePubMedGoogle Scholar
- Impellizzeri D, Talero E, Siracusa R, Alcaide A, Cordaro M, Maria ZJ, et al. Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice. Br J Nutr. 2015;114(6):853–65.View ArticlePubMedGoogle Scholar
- Gerin F, Sener U, Erman H, Yilmaz A, Aydin B, Armutcu F, et al. The effects of quercetin on acute lung injury and biomarkers of inflammation and oxidative stress in the rat model of sepsis. Inflammation. 2015;39(2):700–5.View ArticleGoogle Scholar
- Chambers RC, Scotton CJ. Coagulation cascade proteinases in lung injury and fibrosis. Proc Am Thorac Soc. 2012;9(3):96–101.View ArticlePubMedGoogle Scholar
- Yan Z, Kui Z, Ping Z. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev. 2014;13(10):1020–5.View ArticlePubMedGoogle Scholar
- Gicquel T, Victoni T, Fautrel A, Robert S, Gleonnec F, Guezingar M, et al. Involvement of purinergic receptors and NOD-like receptor-family protein 3-inflammasome pathway in the adenosine triphosphate-induced cytokine release from macrophages. Clin Exp Pharmacol Physiol. 2014;41(4):279–86.View ArticlePubMedGoogle Scholar
- Gui YS, Wang L, Tian X, Li X, Ma A, Zhou W, et al. mTOR Over activation and compromised autophagy in the pathogenesis of pulmonary fibrosis. PLoS One. 2015;10(9):e0138625.View ArticlePubMedPubMed CentralGoogle Scholar
- Shi K, Jiang J, Ma T, Xie J, Duan L, Chen R, et al. Dexamethasone attenuates bleomycin-induced lung fibrosis in mice through TGF-β, Smad3 and JAK-STAT pathway. Int J Clin Exp Med. 2014;7(9):2645–50.PubMedPubMed CentralGoogle Scholar
- Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Annu Rev Pathol. 2014;9:157–79.View ArticlePubMedGoogle Scholar
- Gomer RH. New approaches to modulating idiopathic pulmonary fibrosis. Curr Allergy Asthma Rep. 2013;13(6):607–12.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang Y, Zhang Y, Jiang R. Early traditional Chinese medicine bundle therapy for the prevention of sepsis acute gastrointestinal injury in elderly patients with severe sepsis. Sci Rep. 2017;7:46015.View ArticlePubMedPubMed CentralGoogle Scholar
- Tian T, Chen C, Yang F, Tang J, Pei J, Shi B, et al. Establishment of apoptotic regulatory network for genetic markers of colorectal cancer and optimal selection of traditional Chinese medicine target. Saudi J Biol Sci. 2017;24(3):634–43.View ArticlePubMedPubMed CentralGoogle Scholar
- Chu H, Sun P, Yin J, Liu G, Wang Y, Zhao P, et al. Integrated network analysis reveals potentially novel molecular mechanisms and therapeutic targets of refractory epilepsies. PLoS One. 2017;12(4):e0174964.View ArticlePubMedPubMed CentralGoogle Scholar
- Scheller J, Chalaris A, Garbers C, Rose-John S. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 2011;32(8):380–7.View ArticlePubMedGoogle Scholar
- Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319–35.View ArticlePubMedGoogle Scholar
- Liu B, Li RR, Zhang JJ, Meng C, Zhang J, Song XD, et al. MicroRNA-708-3p as potential IPF therapeutic by targeting ADAM17 through GATA/STAT3 signal pathway in idiopathic pulmonary fibrosis. Exp Mol Med. 2018;50:e465.View ArticlePubMedPubMed CentralGoogle Scholar
- Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393–407.View ArticlePubMedGoogle Scholar